This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) due to the continued procedure recovery and the strength of emerging markets.
Bruker (BRKR) Launches the SciY Platform of Software Solutions
by Zacks Equity Research
Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.
Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.
Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems
by Zacks Equity Research
Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
by Zacks Equity Research
The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
OrthoPediatrics (KIDS) Unveils GIRO for Pediatric Orthopedics
by Zacks Equity Research
The GIRO Growth Modulation System by OrthoPediatrics (KIDS) introduces a tether device designed specifically for pediatric patients.
Integra (IART) Completes Enrollment in the DuraSorb IDE Study
by Zacks Equity Research
Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.
Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Wall Street Analysts Predict a 27.68% Upside in Haemonetics (HAE): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 27.7% upside potential for Haemonetics (HAE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies
by Zacks Equity Research
Organigram's (OGI) SHRED X Heavies is not only the first infused pre-roll in the SHRED product portfolio but also joins a lineup of value-driven, convenient and bold-flavored offerings.
Syneos Health (SYNH) Collaborates With uMotif for New Platform
by Zacks Equity Research
Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.
VREX or HAE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
VREX vs. HAE: Which Stock Is the Better Value Option?
Medtronic's (MDT) MiniMed 780G System Favored by New Data
by Zacks Equity Research
Medtronic (MDT) presents the clinical and real-world data on the MiniMed 780G system at ADA Scientific Sessions in San Diego.
Haemonetics (HAE) Gets FDA Clearance for NexSys PCS Upgrades
by Zacks Equity Research
Haemonetics (HAE) receives FDA clearance for the advancements made to the NexSys PCS plasma collection system.
CVS Health (CVS) Retail Arm Continues to Grow Amid Rising Costs
by Zacks Equity Research
CVS Health (CVS) continues to give high priority to digital engagement, after surpassing 50 million unique digital customers in the first quarter.
Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches
by Zacks Equity Research
Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.
SenesTech (SNES) New Alliance to Aid Expansion in South Africa
by Zacks Equity Research
NSPCA is also working on recommending SenesTech's (SNES) ContraPest to private and state entities and to assist with regulatory issues.
Insulet (PODD) Launches the Omnipod 5 AID System in the UK
by Zacks Equity Research
Insulet (PODD) commercializes its revolutionary Omnipod 5 AID System in the United Kingdom.
Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB
by Zacks Equity Research
Surmodics' (SRDX) SurVeil DCB is indicated to treat percutaneous transluminal angioplasty in peripheral artery disease patients. Abbott will initiate commercialization of SurVeil DCB, per a deal with Surmodics.
Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced
by Zacks Equity Research
Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.
Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes
by Zacks Equity Research
Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.
QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing
by Zacks Equity Research
The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.
Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection
by Zacks Equity Research
The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.
ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
by Zacks Equity Research
ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.